Evotec stock holds near 52-week low as revenue drops in first half

Published on 09/12/2026 at 14:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock closed at EUR 3.03 on September 11, 2026, only 1.9 percent above its 52-week low of EUR 2.97. The biotech group’s H1 2026 revenue fell 19.2 percent year on year, keeping pressure on the shares.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) is trading close to its 52-week low after a marked decline in revenue in the first half of 2026, with the shares closing at EUR 3.03 on Xetra on September 11, 2026, just 1.9 percent above the 52-week low of EUR 2.97 per Trading-Treff data.

Revenue decline weighs on Evotec

According to Trading-Treff on September 12, 2026, Evotec reported that its revenue in the first half of 2026 declined by 19.2 percent compared with the prior-year period, signaling a challenging operating environment for the biotech services provider.

Per the same report from Trading-Treff, the company’s share price performance reflects this pressure, with the stock closing at EUR 3.03 on September 11, 2026 and standing only 1.9 percent above the 52-week low of EUR 2.97, a narrow cushion that underlines investor caution.

Stock trades close to 52-week low

The closing level of EUR 3.03 on September 11, 2026 implies that Evotec stock remains very close to its recent 52-week low of EUR 2.97, highlighting how the market has repriced the company following the 19.2 percent drop in first-half 2026 revenue as reported by Trading-Treff.

For investors, the combination of a nearly 20 percent year-on-year revenue decline in H1 2026 and a share price only 1.9 percent above the 52-week low suggests that confidence in Evotec’s near-term earnings trajectory remains subdued, and the stock may react sensitively to upcoming operating updates.

Next quarterly update in November

Looking ahead, according to Trading-Treff, Evotec plans to present its results for the third quarter of 2026 on November 5, 2026, a date that will be closely watched as investors look for signs of stabilization or improvement after the first-half revenue decline.

This upcoming Q3 2026 report represents an important checkpoint for Evotec stock, as any indication that revenue trends are stabilizing or that cost measures are supporting margins could help determine whether the current price level near the 52-week low marks a base or whether further downside risk remains.

Evotec stock price snapshot

Evotec stock closed at EUR 3.03 on Xetra on September 11, 2026, with the closing level sitting just above the 52-week low of EUR 2.97 reported by Trading-Treff, underscoring the cautious stance of the market toward the company ahead of the planned Q3 2026 results release on November 5, 2026.